Evidence map›Paper›PMID 32404975›Full record

GuidelineBone marrow transplantation2020

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy.

Per Ljungman, Malgorzata Mikulska, Rafael de la Camara, Grzegorz W Basak, Christian Chabannon, Selim Corbacioglu, Rafael Duarte, Harry Dolstra, Arjan C Lankester, Mohamad Mohty and 9 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readPractice GuidelineReview
In one paragraph

Guideline in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04760184 (Impact of COVID-19 on Patients Treated With Autologous Hematopoietic Stem Cell Transplantation in Sweden - a Retrospective Cohort Study), which is not on this map. Cited by 129 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 8 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04760184 completednot on this mapstarted 2021, after this paper: background citation

Impact of COVID-19 on Patients Treated With Autologous Hematopoietic Stem Cell Transplantation in Sweden - a Retrospective Cohort Study

TypeobservationalSponsorUppsala UniversityRan2021 to 2021Enrolled20ConditionsCovid19, Myeloma Multiple, Malignant Lymphoma, Hematologic NeoplasmsArmsAutologous stem cell transplantation
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 8 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Guideline
  8. Pooled it
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 8 countries.

Per LjungmanDepartment of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Per.Ljungman@ki.se.ORCID http://orcid.org/0000-0002-8281-3245
Malgorzata MikulskaDivision of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy.
Rafael de la CamaraDepartment of Hematology, Hospital de la Princesa, Madrid, Spain.ORCID http://orcid.org/0000-0002-8189-5779
Grzegorz W BasakDepartment of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Christian ChabannonInstitut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.
Selim CorbaciogluPediatric Hematology, Oncology and Stem Cell Transplantation Department, University of Regensburg, Regensburg, Germany.
Rafael DuarteServicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Harry DolstraLaboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Arjan C LankesterWillem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Centre Leiden, Leiden, the Netherlands.
Mohamad MohtyDepartment of Hematology, Hospital Saint Antoine, Paris, France.
Silvia MontotoSt. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
John MurrayThe Christie NHS Foundation Trust, Manchester, UK.
Régis Peffault de LatourBMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.
John A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Ibrahim Yakoub-AghaCHU de Lille, Univ Lille, INSERM, U1285, Lille, France.
Bregje VerhoevenFoundation Hematon, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0001-8668-6039
Nicolaus KrögerDepartment of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Jan StyczynskiPediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.ORCID http://orcid.org/0000-0002-3158-119X
European Society for Blood and Marrow Transplantation
Inserm · FRLeiden University · NLSt Bartholomew's Hospital · GBUniversität Hamburg · DEHospital Universitario de La Princesa · ESHospital Universitario Puerta de Hierro Majadahonda · ESKarolinska Institutet · SEKarolinska University Hospital · SEMedical University of Warsaw · PLNicolaus Copernicus University · PLRadboud University Nijmegen · NLSheffield Teaching Hospitals NHS Foundation Trust · GBThe Christie NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT's scientific council and board. This work intends to provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the COVID-19 pandemic has passed.

Indexed as

BetacoronavirusCoronavirus InfectionsHematopoietic Stem Cell TransplantationImmunotherapy, AdoptivePandemicsPneumonia, ViralAccreditationAllograftsClinical Laboratory TechniquesContinuity of Patient CareCOVID-19COVID-19 TestingCross InfectionDelivery of Health CareEuropeHealth Personnel

Identifiers

PMID32404975
PMCPMC7220575
OpenAlexW3025499341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.